Achieve Life Sciences is a specialty pharmaceutical company committed to addressing the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

Cytisinicline (also known as cytisine) is a plant-based alkaloid with a high binding affinity to the α4β2 nicotine receptor. Over the past 20 years, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.  Achieve’s focus is to address the global smoking health epidemic by making cytisinicline widely available.

The Phase 3 ORCA-2 trial of cytisinicline has reached its enrollment target of 750 adult smokers. 

ORCA-2 is designed to evaluate the safety and efficacy of 3 mg cytisinicline dosed 3 times daily compared to placebo in adult cigarette smokers who want to quit.

The trial is currently being conducted at 17 sites in the U.S.

Learn More